Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,205 INR | +0.88% | +2.33% | +40.95% |
May. 30 | Transcript : Glenmark Pharmaceuticals Limited - Analyst/Investor Day | |
May. 29 | Assertio Therapeutics Names Brendan O'Grady as Chief Executive | MT |
Sales 2024 | 118B 1.41B | Sales 2025 * | 139B 1.66B | Capitalization | 337B 4.04B |
---|---|---|---|---|---|
Net income 2024 | -15.02B -180M | Net income 2025 * | 13.25B 159M | EV / Sales 2024 | 2.29 x |
Net Debt 2024 * | 19.84B 238M | Net cash position 2025 * | 23.55B 282M | EV / Sales 2025 * | 2.25 x |
P/E ratio 2024 |
-18
x | P/E ratio 2025 * |
25.3
x | Employees | 15,556 |
Yield 2024 * |
0.19% | Yield 2025 * |
0.25% | Free-Float | 49.03% |
Latest transcript on Glenmark Pharmaceuticals Limited
1 day | +0.90% | ||
1 week | +2.44% | ||
Current month | +3.84% | ||
1 month | +17.67% | ||
3 months | +26.13% | ||
6 months | +47.10% | ||
Current year | +41.10% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | - | |
Chief Executive Officer | 54 | 98-10-11 | |
Ulhas Dhuppad
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 20-08-13 | |
Cherylann Pinto
BRD | Director/Board Member | 56 | 99-10-05 |
Chief Executive Officer | 54 | 98-10-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 4 M€ | -4.41% | - | |
0.01% | 114 M€ | +4.36% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 1,205 | +0.88% | 529 334 |
24-06-07 | 1,194 | -1.30% | 818,364 |
24-06-06 | 1,210 | +2.22% | 769,796 |
24-06-05 | 1,184 | +5.45% | 935,489 |
24-06-04 | 1,122 | -4.58% | 2,199,037 |
Delayed Quote NSE India S.E., June 10, 2024 at 03:20 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.10% | 4.04B | |
+20.33% | 43.3B | |
+23.67% | 22.22B | |
+18.07% | 15.43B | |
+21.97% | 14.48B | |
+56.80% | 12.72B | |
-0.05% | 6.79B | |
-10.69% | 6.71B | |
-8.87% | 5.73B | |
+14.68% | 5.5B |
- Stock Market
- Equities
- GLENMARK Stock